I am passionate about the care of patients with myeloma and my goal is to bring cutting edge clinical trials and current therapies including – MRD to guide limited duration therapy, use of immunotherapy including Bispecific antibodies and CART cells to treat myeloma. A clinical trialist and investigator with over 50 peer-reviewed publications, reviews and book chapters, I develop risk-based approaches for the treatment of multiple myeloma. My research interests are two fold – how to sequence immunotherapy and how to prevent myeloma relapsing after immunotherapy. I am the Principal investigator of investigator initiated clinical trials to test these concepts. Apart from this I am also involved in research in understanding and improving side effects of immunotherapy in elderly patients with myeloma.